Gallstones News and Research RSS Feed - Gallstones News and Research

Gallstones are small, pebble-like substances that develop in the gallbladder. The gallbladder is a small, pear-shaped sac located below your liver in the right upper abdomen. Gallstones form when liquid stored in the gallbladder hardens into pieces of stone-like material. The liquid—called bile—helps the body digest fats. Bile is made in the liver, then stored in the gallbladder until the body needs it. The gallbladder contracts and pushes the bile into a tube—called the common bile duct—that carries it to the small intestine, where it helps with digestion.
Mayo Clinic article provides better understanding on potentially devastating liver disease

Mayo Clinic article provides better understanding on potentially devastating liver disease

An article published today in the New England Journal of Medicine updates the medical community on a potentially devastating liver disease that afflicts approximately 29,000 Americans. [More]
Loyola specialists cure patient’s acute pancreatitis

Loyola specialists cure patient’s acute pancreatitis

Larry Jacob got the call every parent fears. His daughter was sick, away at college and needed help. Mr. Jacob left his home in the Chicago suburbs and was driving to Western Illinois University when he suddenly doubled over in pain. [More]
NYU Lutheran offers many treatment options for kidney stone sufferers

NYU Lutheran offers many treatment options for kidney stone sufferers

Frederick A. Gulmi, MD, chief of urology at NYU Lutheran, cautions anyone who has never had a bout with kidney stones. [More]
Two simple measures can help decrease incidence of POCD in older patients

Two simple measures can help decrease incidence of POCD in older patients

Post-operative cognitive dysfunction (POCD), a condition mostly observed in older patients following surgery under general anesthesia, is characterized by impaired memory and concentration. The impairment may be temporary or permanent and incapacitating. [More]
Gallstones, statins increase risk of acute pancreatitis, shows study

Gallstones, statins increase risk of acute pancreatitis, shows study

Idiopathic pancreatitis is often caused by small gallstones that are difficult to observe prior to surgery, shows a study from the University of Eastern Finland. Small gallstones were found in surgery from two out of three idiopathic pancreatitis patients. [More]
FDA orders three duodenoscope manufacturers in the U.S. to conduct postmarket surveillance studies

FDA orders three duodenoscope manufacturers in the U.S. to conduct postmarket surveillance studies

The U.S. Food and Drug Administration today ordered the three manufacturers of duodenoscopes marketed in the U.S. to conduct postmarket surveillance studies to better understand how the devices are reprocessed in real-world settings. [More]
New review article analyzes pros and cons of different treatment approaches to gallbladder disease

New review article analyzes pros and cons of different treatment approaches to gallbladder disease

More than 25 million Americans have gallstones, and each year about 1 million new cases are diagnosed. Each year about 1.8 million people develop abdominal pain as a result of gallstones and go see a doctor about it. About 40 percent of these, more than 725,000 people a year, ultimately have surgery to resolve the problem. [More]
MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD (Merck & Co., Inc., Kenilworth, New Jersey, USA) today announced that on 22 June the European Commission approved SIMPONI (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA). [More]
Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

Lilly Diabetes Alliance, Boehringer Ingelheim to present study results at ADA’s Scientific Sessions

The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio at the 75th American Diabetes Association's (ADA) Scientific Sessions® in Boston, June 5-9. [More]
Aflatoxin exposure associated with increased risk of gallbladder cancer

Aflatoxin exposure associated with increased risk of gallbladder cancer

In a small study in Chile that included patients with gallbladder cancer, exposure to aflatoxin (a toxin produced by mold) was associated with an increased risk of gallbladder cancer, according to a study in the May 26 issue of JAMA. [More]

Galmed reports net loss of $2.5 million for first quarter 2015

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, today announced financial results for the three months ended March 31, 2015. [More]
Pocket-sized ultrasound device reduce need for further testing in inpatient and outpatient settings

Pocket-sized ultrasound device reduce need for further testing in inpatient and outpatient settings

Results from a study presented today at The International Liver Congress 2015 demonstrate that the use of a pocket-sized ultrasound device (PUD) helps to reduce the need for further testing in both the inpatient and outpatient setting. [More]
Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S., including Walgreens and Rite Aid. [More]
Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. [More]
Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Galmed Pharmaceuticals Ltd. ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it purchased 60 EndoPAT™ devices and accessories from Itamar Medical Ltd. [More]
Gallbladder removal surgery can wait until regular working hours, researchers find

Gallbladder removal surgery can wait until regular working hours, researchers find

Laparoscopic cholecystectomy, a minimally invasive procedure to remove the gallbladder, is one of the most common abdominal surgeries in the U.S. Yet medical centers around the country vary in their approaches to the procedure with some moving patients quickly into surgery while others wait. [More]
Study: Younger, older people likelier to visit ER repeatedly with gallstone pain before surgery

Study: Younger, older people likelier to visit ER repeatedly with gallstone pain before surgery

Gallstone pain is one of the most common reasons patients visit emergency rooms. Figuring out who needs emergency gallbladder removal and who can go home and schedule surgery at their convenience is sometimes a tricky question, and it isn't always answered correctly. [More]
Researchers recommend laparoscopic surgical removal of gallbladder for pediatric patients

Researchers recommend laparoscopic surgical removal of gallbladder for pediatric patients

A recent study conducted by Mayo Clinic researchers recommends laparoscopic cholecystectomies (surgical removal of the gallbladder) for pediatric patients suffering from gallstones and other gallbladder diseases. [More]
Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Galmed reports net loss of $3.9 million for six months ended June 30, 2014

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced financial results for the period ended June 30, 2014. [More]
Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed reductions from baseline A1c at 18 (eight trials) and 24 (six trials) weeks compared to placebo in African-American adults with type 2 diabetes (T2D), [More]
Advertisement